Daina Graybosch
Stock Analyst at Leerink Partners
(0.75)
# 4,109
Out of 5,246 analysts
93
Total ratings
38.1%
Success rate
-19.22%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IPSC Century Therapeutics | Downgrades: Market Perform | $7 → $2 | $2.26 | -11.50% | 5 | Nov 17, 2025 | |
| IPHA Innate Pharma | Downgrades: Market Perform | $10 → $2 | $1.83 | +9.29% | 11 | Sep 18, 2025 | |
| XLO Xilio Therapeutics | Initiates: Outperform | $28 | $8.28 | +238.16% | 1 | Aug 6, 2025 | |
| ADAG Adagene | Initiates: Outperform | $7 | $3.75 | +86.67% | 1 | Aug 6, 2025 | |
| SMMT Summit Therapeutics | Initiates: Underperform | $12 | $16.62 | -27.80% | 1 | Jun 11, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $122.41 | -2.79% | 19 | Jan 13, 2025 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $60 → $20 | $4.95 | +304.04% | 8 | May 15, 2024 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $75 → $45 | $66.61 | -32.44% | 10 | Feb 24, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $2.25 | +344.44% | 7 | Jan 6, 2023 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $40 → $38 | $23.43 | +62.19% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $4.18 | +91.39% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $92.14 | +143.11% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $3.03 | +890.10% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $0.4436 | +3,732.28% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $2.80 | +221.43% | 4 | Feb 25, 2022 |
Century Therapeutics
Nov 17, 2025
Downgrades: Market Perform
Price Target: $7 → $2
Current: $2.26
Upside: -11.50%
Innate Pharma
Sep 18, 2025
Downgrades: Market Perform
Price Target: $10 → $2
Current: $1.83
Upside: +9.29%
Xilio Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $28
Current: $8.28
Upside: +238.16%
Adagene
Aug 6, 2025
Initiates: Outperform
Price Target: $7
Current: $3.75
Upside: +86.67%
Summit Therapeutics
Jun 11, 2025
Initiates: Underperform
Price Target: $12
Current: $16.62
Upside: -27.80%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $122.41
Upside: -2.79%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $60 → $20
Current: $4.95
Upside: +304.04%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $75 → $45
Current: $66.61
Upside: -32.44%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $2.25
Upside: +344.44%
Arcus Biosciences
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $23.43
Upside: +62.19%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $4.18
Upside: +91.39%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $92.14
Upside: +143.11%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $3.03
Upside: +890.10%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $0.4436
Upside: +3,732.28%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $2.80
Upside: +221.43%